Affiliation:
1. I.I. Mechnikov North-West State Medical University
2. Clinical Rheumatological Hospital No. 25
Abstract
The article presents the relevance of the problem of postmenopausal osteoporosis (OP) in modern medicine, due to the social and economic consequences of fractures. The pathogenetic mechanisms of its formation are highlighted, indicating that during postmenopausal women amid estrogen deficiency, there is a violation of bone remodeling processes with increased bone resorption and decreased bone formation. Modern recommendations of the pathogenetic therapy of OP are presented, in which it is noted that the drugs of the first choice are drugs of the bisphosphonate class (BF). The ability of BF to suppress the pathological resorption of bone tissue and stimulate bone formation determines their therapeutic effect in OP. One of the drugs of the BF class is alendronate. In the treatment with alendronate, the processes of resorption by osteoclasts are suppressed and the processes of bone metabolism are restored to the premenopausal level, microarchitectural disturbances and bone loss are prevented. It has been demonstrated that the processes of bone metabolism remain stable during prolonged treatment with alendronate for 10 years, while the accumulation of the drug in the bone does not lead to excessive suppression of bone metabolism, but rather remains at the premenopausal level. The data of international and Russian randomized placebo-controlled trials (RCTs) are presented, which indicate the high effectiveness of alendronate at a dose of 70 mg 1 time / week in the treatment of primary OP in postmenopausal women: it had a positive effect on bone mineral density (BMD), reduced pain and, as a result, reduced the restriction of physical activity of patients. Quite good tolerability of the drug was noted, side effects in the treatment group were comparable to those in the placebo group. An analysis of the action of alenadronate shows that it has an aftereffect within a 12-month period after the end of treatment in relation to the BMD of the spine.
Reference44 articles.
1. Lesnyak O.M., Baranova I.A., Belova K.Y., Gladkova Ye.N., Evstigneeva L.P., Ershova O.B. et al. Osteoporosis in Russian Federation: epidemiology, socio-medical and economical aspects (review). Travmatologiya i ortopediya Rossii = Traumatology and Orthopedics of Russia. 2018;24(1):155–168. (In Russ.) doi: 10.21823/2311-2905-2018-24-1-155-168.
2. Hernlund E., Svedbom A., Ivergård M., Compston J., Cooper C., Stenmark J. et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136. doi: 10.1007/s11657-013-0136-1.
3. Fominykh M.P., Popov A.A., Iimoiherova P.V., Akimova A.V., Tagiltseva N.V., Stryukova O.Yu. Osteopenia and osteoporosis of the distal forearm in women in menopause. Terapevticheskiy arkhiv = Therapeutic Archive. 2007:(4):40–41. (In Russ.) Available at: https://elibrary.ru/item.asp?id=9538885.
4. Lesnyak O.M., Toportsova N.V. Federal clinical guidelines for the diagnosis and treatment of osteoporosis. Moscow; 2014. 26 р. (In Russ.) Available at: https://rheumatolog.su/media/media/2018/07/18/clinrec_osteoporoz.pdf.
5. Lesnyak O.M., Benevolenskaya L.I. (eds.). Osteoporosis. 2nd ed. Moscow: GEOTAR-Media; 2009. 272 p. (In Russ.) Available at: https://endoinfo.ru/guidelines/rus_osteoporos2009.pdf.